Patients taking tofacitinib (Xeljanz) in the drug's late-stage and post-marketing studies were more likely than those on ...

Besides knowing what different patterns of infection exist across advanced therapies, what is “really important” is how ...

The combination of tofacitinib plus zimlovisertib improved outcomes over tofacitinib alone in patients with rheumatoid arthritis. Ritlecitinib failed to show additive efficacy in rheumatoid ...

Xeljanz and Xeljanz XR contain the active drug tofacitinib. They belong to a class of drugs called Janus kinase (JAK) inhibitors. Xeljanz and Xeljanz XR inhibit (block the activity of) an enzyme ...

Reporting in ACR Open Rheumatology, Zavoriti and Miossec provide data that might explain the prothrombotic effects of the JAK inhibitor tofacitinib. Modifications enhancing degradation resistance ...

The post-marketing ORAL Surveillance safety study showed that JAK inhibitor Xeljanz (tofacitinib) was associated with a higher rate of heart attacks and cancer than a TNF inhibitor in patients ...

A randomized controlled safety trial reported numerically higher rates of major cardiovascular events with tofacitinib ... arthritis treated with Janus kinase inhibitors compared to biologic ...

Over half of patients with alopecia areata develop new-onset acne on JAK inhibitors, especially those with a personal history ...